Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gelb, D. Tashkin, B. Make, X. Zhong, E. Garcia Gil, C. Caracta (Lakewood, Los Angeles, Denver, Jersey City, United States Of America; Barcelona, Spain). Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study. Eur Respir J 2012; 40: Suppl. 56, 2118

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021 Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Source: ERJ Open Res 2016: 00101-2015 Year: 2016 Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Source: Eur Respir J 2002; 20: 1138-1146 Year: 2002 Comparison of ciclesonide 160 μg/d with budesonide 400 μg/d in a randomised, double-blind study in children with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 711s Year: 2006 Efficacy and safety of montelukast sodium on adult bronchial asthma in a multicenter comparative double-blind clinical study with pranlukast hydrate Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Efficacy and safety of montelukast sodium on adult bronchial asthma in a multicentre comparative double-blind clinical study with pranlukast hydrate Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012